Manufacturing of vaccines and viral vectors

Viral vector video series

Cytiva scientists lay out the current trends and challenges in manufacturing viral vectors

SEE THE VIDEOS

Scalable manufacturing of viral vectors

More efficacious and targeted treatments are a constant endeavor of the pharmaceutical industry.

Alternatives to traditional therapies, such as viral vector systems, are explored to meet this need.

Purification platforms for bacterial capsular polysaccharides

As vaccines are often distributed by national health authorities, production costs need to be low to enable a global reach of the vaccines.

Manufacturing processes based on modern technologies can help enhance productivity and result in more cost-efficient and easily scaled processes.

Cell-based flavivirus production

To meet the needs of preventive campaigns, millions of vaccine doses would be required, making production both space- and resource-consuming.

Alternative production strategies, such as cell-based virus propagation and single-use equipment can improve agility to meet market demands.

Process train comprising single-use equipment

Influenza vaccine production using single-use equipment

Single-use systems are well accepted by biomanufacturers and bring benefits such as reduced and delayed capital investments and a shift from fixed to variable costs.

Single-use equipment provide the opportunity for more batches produced per year, while minimizing costs and increasing revenue.

Vaccines and viral vectors

Viral vector video series

Scalable manufacturing of viral vectors

Purification platforms for bacterial capsular polysaccharides

Cell-based flavivirus production

Influenza vaccine production using single-use equipment

Capto PlasmidSelect

Capto AVB

Capto Core 400

Capto Core 700

FIND OUT MORE